Table 1. Characteristics of included studies.
| study | year | MUC | high/positive | low/negative | HRa | 95%CI | NOS | region | Methodb | Locationc | Data resource |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Takikita, M. | 2009 | MUC1 | 139 | 15 | 1.6 | 0.9–3.0 | 8 | USA | IHC | cytoplasm | SEER-TMA |
| MUC5 | 99 | 55 | 1.4 | 1.0–2.1 | 8 | USA | IHC | cytoplasm | SEER-TMA | ||
| Striefler, J. K. | 2021 | MUC1 | 23 | 115 | 2.17 | 1.35–3.45 | 7 | Germany | IHC | cytoplasm | CONKO-001 Study |
| Sierzega, M. | 2016 | MUC1 | NA* | NA | 0.60 | 0.28–1.27 | 7 | Poland | IHC | NA | clinical data |
| Jonckheere, N. | 2020 | MUC1 | NA | NA | 4.49 | 1.64–12.33 | 7 | France | mRNA level | cytoplasm | TCGA |
| MUC4 | NA | NA | 3.94 | 1.81–8.61 | 7 | France | mRNA level | cytoplasm | TCGA | ||
| MUC5B | NA | NA | 4.38 | 1.76–10.9 | 7 | France | mRNA level | cytoplasm | TCGA | ||
| MUC16# | NA | NA | 2.53 | 1.47–4.36 | 7 | France | mRNA level | cytoplasm | TCGA | ||
| Hinoda, Y.# | 2003 | MUC1 | 39 | 31 | 1.82 | 1.11–2.98 | 7 | Japan | IHC | membrane or cytoplasm | clinical data |
| Dotan, E.# | 2016 | MUC1 | 10 | 13 | 1.97 | 1.15–3.39 | 6 | USA | IHC | cytoplasm | clinical data |
| Sato, K.# | 2018 | MUC1 | 14 | 15 | 2.47 | 1.25–4.87 | Japan | mRNA | cytoplasm | clinical data | |
| Yokoyama, S. | 2016 | MUC1 | 39 | 11 | 3.36 | 1.44–7.89 | 6 | Japan | DNA methylation level | nucleus | clinical data |
| MUC4 | 29 | 21 | 2.47 | 1.10–5.56 | 6 | Japan | DNA methylation level | nucleus | clinical data | ||
| Zhu, Y. | 2011 | MUC4 | 29 | 28 | 2.50 | 1.33–4.70 | 6 | China | mRNA level | cytoplasm | clinical data |
| Zhu, Y. | 2014 | MUC4 | 33 | 75 | 2.28 | 1.42–3.68 | 7 | China | mRNA level | cytoplasm | clinical data |
| Yang# | 2014 | MUC4 | 48 | 29 | 1.75 | 1.10–2.78 | 6 | China | IHC | NA | clinical data |
| Saitou, M. | 2005 | MUC4 | 21 | 114 | 1.96 | 1.13–3.38 | 6 | Japan | IHC | Cytoplasm or cytomembrane | clinical data |
| Jinfeng, M.# | 2003 | MUC5AC | 21 | 12 | 2.47 | 1.17–5.23 | 6 | Japan | IHC | cytoplasm | clinical data |
| Yamasaki, H.# | 2004 | MUC5AC | 30 | 11 | 0.53 | 0.2–1.41 | 6 | Japan | IHC | Cytoplasm or cytomembrane | clinical data |
| Streppel, M. M. | 2012 | MUC16 | 119 | 81 | 2.00 | 1.36–2.94 | 7 | USA | IHC | cytomembrane | clinical data |
| Shimizu, A. | 2012 | MUC16 | 41 | 62 | 1.94 | 1.13–3.31 | 7 | Japan | IHC | membrane or cytoplasm | clinical data |
| Liang, C. | 2017 | MUC16 | 60 | 50 | 2.39 | 1.52–3.77 | 7 | China | IHC | cytomembrane | clinical data |
| Fan, K.# | 2018 | MUC16c | 56 | 55 | 1.98 | 1.14–3.45 | 8 | China | IHC | NA | clinical data |
* No information about the project was provided in the study.
# The study did not provide HR or 95%CI. The HR and 95%CI were estimates.
a The HR and 95%CI of overall survival (OS) were extracted. If both univariate and multivariate analysis HR existed, multivariate analysis HR was preferred.
b It represented the detection method of mucin expression in the study. IHC referred to the immunohistochemical score to identify mucin expression and mRNA level referred to the expression level of mucin gene in the nucleus by checking the cytoplasmic mRNA content by qt-PCR.
c It represented the localization of mucin.